- Home
- BY vs SANA Comparison
BY vs SANA Comparison
Compare BY & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BY | SANA |
|---|---|---|
| Founded | 1914 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BY | SANA |
|---|---|---|
| Price | $30.77 | $3.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $33.50 | $7.50 |
| AVG Volume (30 Days) | 132.8K | ★ 1.9M |
| Earning Date | 04-22-2026 | 06-10-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | 5.09 | ★ 17.24 |
| EPS | ★ 2.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.06 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.63 | $1.27 |
| 52 Week High | $33.89 | $6.55 |
Technical Indicators
Market Signals| Indicator | BY | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 28.61 |
| Support Level | $25.42 | $2.85 |
| Resistance Level | $31.69 | $3.24 |
| Average True Range (ATR) | 0.85 | 0.26 |
| MACD | -0.26 | -0.07 |
| Stochastic Oscillator | 16.69 | 4.71 |
Price Performance
Historical ComparisonAbout BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.